Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy with EGFR-TKI in Oligometastatic EGFR-Mutated NSCLC
NCT02788058Phase 2Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- May 2016
- Primary completion
- May 2021
01
Overview
Phase 2, randomised trial (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Progression Free Survival at 3 years. Status: unknown.
Beyond the preview
Go deeper on NCT02788058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788058.